Ghent, Belgium – 25 April 202 3 – Sequana Medical NV (Euronext Brussels: SEQUA ) (the " Company " or " Sequana Medica l "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by the Company to attend the Annual General Meeting of Shareholders on Thursday, 25 May 2023. Furthermore, the annual report for the financial year 2022 has been published on Sequana Medical's website and can be accessed here.